In a nutshell This trial is examining the effectiveness of a new cancer vaccine. The main outcomes to be measured are cancer response and side effects. This trial is recruiting in New York and Tennessee, US. The details The standard treatment for most cancers is surgery and chemotherapy. However, chemotherapy has a limited effectiveness and a high...
Read MoreIn a nutshell This trial will investigate the effects of bb2121 in patients with non-responsive multiple myeloma (MM) who have progressed after standard treatment. The percentage of patients who respond and the percentage of patients who respond completely will be the main measures in this study. This study will take place in the United States and...
Read MoreIn a nutshell This trial aims to see if combining two medications, T-DM1 (Kadcycla) and palbociclib (Ibrance) is better than just using T-DM1 in treating HER2+ breast cancer that has spread. The main outcome that will be measured is survival without the cancer growing or spreading. The study is being conducted in Arizona, the United States. The...
Read More
In a nutshell This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell non-Hodgkin’s lymphoma (NHL). The main outcomes to be measured will be the complete response rate and the occurrence of side effects after treatment. This study is recruiting in Miami, Florida, New York City, New York, and Duarte,...
Read MoreIn a nutshell This trial aims to test the effectiveness of adding olaparib (Lynparza) to radiotherapy for inflammatory breast cancer. The main outcome measured will be how long the patients survive without the disease coming back in its invasive form. The study is being conducted in the United States. The details Inflammatory breast cancer can be...
Read MoreIn a nutshell This trial aims to test the effectiveness of a new drug called RRx-001 in patients with small cell carcinoma. The main outcome measured will be how long the patients go without cancer growing or spreading (progression-free survival). The study is being conducted in the United States, Orange City, Florida. The details...
Read MoreIn a nutshell This trial aims to evaluate the safety and effectiveness of the combination of nivolumab (Opdivo), ipilimumab (Yervoy), and paclitaxel (Taxol) for treating lung cancer. The main outcome that will be measured is survival without the tumor growing or spreading. The study is taking place in Durham, North Carolina, the United States. The...
Read MoreIn a nutshell This trial examined the effectiveness of combining the targeted therapy drug pembrolizumab (Keytruda) with chemotherapy at treating certain types of advanced non-small-cell lung cancer. The trial concluded that this combination is more beneficial than chemotherapy alone for treating this subset of patients. Some background PD-1...
Read MoreIn a nutshell This study examined the exercise behavior and physical fitness in patients with advanced lung cancer. The authors concluded that regular exercise and therefore physical fitness is reduced after diagnosis of advanced lung cancer. Some background Cancer patients frequently have reduced physical ability and quality of life due to fatigue...
Read MoreIn a nutshell This study looked at the anticancer effect of metformin (Glucophage), a drug commonly used to treat type 2 diabetes. The authors concluded that metformin in combination with current cancer therapies such as chemotherapy improved progression free survival in patients with advanced non-small-cell lung cancer. Some background Patients with...
Read More
In a nutshell This study aims to test the safety and effectiveness of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. The main outcome to be measured will be the presence of disease. This study is being conducted in New Jersey, and New York. The details Multiple...
Read More
In a nutshell This study aims to compare ixazomib plus dexamethasone versus pomalidomide plus dexamethasone on survival in participants with relapse and/or refractory multiple myeloma. The outcome to be measured is the duration of time until disease progresses (worsens). The details Multiple myeloma is a cancer of the plasma cells in the...
Read More
